GlobeNewsWire
28 Sept 2026, 06:49 UTC · 6h ago
Verdict
Headline takes no side. We score 9887.HK +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Japan's MHLW granted Orphan Drug Designation (ODD) to opamtistomig (LBL-024) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC).
Newannounced today Sept. 28, 2026
So whatThis provides a regulatory foothold in a $73 billion market, potentially speeding up the timeline for the first Japanese revenue stream.
More positive than 66% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Leads Biolabs submitted a New Drug Application (NDA) for opamtistomig to China's NMPA in August 2026, which is currently under technical review.
Priced insubmitted in August 2026
So whatGiven the Priority Review status granted in July, a decision on the primary China market is expected within the next 6-12 months.
More positive than 54% of claims this week
Opamtistomig is currently being evaluated across 14 indications, including one pivotal single-arm registrational study and one confirmatory Phase III study.
Priced indescribes current state of evaluation
So whatThe high number of proof-of-concept studies (9) suggests significant R&D burn through 2027 before broad commercialization.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company received Orphan Drug Designation in Japan for its proprietary antibody opamtistomig, facilitating accelerated development and commercialization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
13h ago
—
No price for 9887.HK right now — the quote feed didn't answer.
9887.HK chart →
